NVS: NOVARTIS A G Profile

Ticker

Advertisement

Choose a Broker

Dynamic view of the market

Symbol	Value	Change	Percentage Change
DJIA	11,348.14	-1.14	-0.01%
NASDAQ	2,306.54	26.43	1.16%
S&P 500	1,254.75	2.21	0.18%

NOVARTIS A G

NVS

Stock price

58.79 -1.06 -1.77%

as of 03:06 PM EDT on 07/25/2008 in USD (NYSE Delay: 20 mins.)
Extended Hours

— — —

Analyst Consensus

Buy
Analyst Consensus

Strong Buy

Buy

Hold

Sell

Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: NVS

Insightful information about industries, companies, and the people who lead them.

Learn More.

2007 Sales	2007 Sales Growth	2007 Net Income	2007 Employees
$38,947,000,000	6.0%	$11,968,000,000	98,200

Key Executives: NVS

Name	Title	Officer Since
Dr. Daniel Vasella	CEO	1/1/96
Dr. Raymund Breu	CFO	-
Srikant Datar, Ph.D.	Director	1/1/03
Dr. Ing. Wendelin Wiedeking	Director	1/1/03
Mark C. Fishman, M.D.	President, Divisional	-
Juergen Brokatzky-Geiger, Ph.D.	Other Corporate Officer	-
Andreas Rummelt, Ph.D.	CEO, Divisional	-
Andreas von Planta, Ph.D.	Director	2/28/06

View All Key Executives

Raymund Breu graduated from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, with a Ph.D. in mathematics. In 1975, he joined the Treasury Department of the Sandoz Group, and in 1982, became the Head of Finance for the Sandoz affiliates in the UK. In 1985, he was appointed Chief Financial Officer of Sandoz Corporation in New York, where he was responsible for all Sandoz Finance activities in the US. In 1990, he became Group... View Full Profile

Dr. Raymund Breu

Srikant Datar became a member of the Board of Directors in 2003. He has been a member of the Audit and Compliance Committee since 2007. The Board has appointed him as Audit Committee Financial Expert. He qualifies as an independent Non-Executive Director. Srikant Datar is a member of the Board of ICF International, Fairfax, Virginia, USA, and KPIT-Cummins Infosystem Ltd., Pune, India. He currently holds the Arthur Lowes Dickinson Professorship at... View Full Profile

Srikant Datar, Ph.D.

Wendelin Wiedeking was elected as a member of the Board of Directors in 2003. He qualifies as an independent Non-Executive Director. Wendelin Wiedeking is Chairman of the Executive Board of Porsche Automobil Holding SE and of Dr.-Ing. h.c. F. Porsche AG, Germany. Born in Ahlen, Germany, Wendelin Wiedeking studied mechanical engineering and worked as a scientific assistant in the Machine Tool Laboratory of the Rhine-Westphalian College of Advanced... View Full Profile

Dr. Ing. Wendelin Wiedeking

Dr. Fishman graduated with a B.A. from Yale College in 1972 and an M.D. from Harvard Medical School in 1976. He was appointed President of the Novartis Institutes for BioMedical Research (NIBR) in 2002. Before joining Novartis, Dr. Fishman was Chief of Cardiology and Director of the Cardiovascular Research Center at the Massachusetts General Hospital in Boston, Massachusetts, and Professor of Medicine at Harvard Medical School. Dr. Fishman serves... View Full Profile

Mark C. Fishman, M.D.

Juergen Brokatzky-Geiger graduated with a Ph.D. in chemistry from the University of Freiburg, Germany in 1982. He joined Ciba-Geigy Ltd. in 1983 as a Laboratory Head in the Pharmaceuticals Division. After a job rotation in Summit, New Jersey from 1987 to 1988, he held positions of increasing responsibility in Research and Development including Group Leader of Process R&D, Head of Process R&D, and Head of Process Development and Pilot Plant... View Full Profile

Juergen Brokatzky-Geiger, Ph.D.

Andreas Rummelt graduated with a Ph.D. in pharmaceutical sciences from the University of Erlangen-Nuernberg, Germany. He joined Sandoz Pharma Ltd. in 1985 and held various positions with increasing responsibility in Development. In 1994 he was appointed Head of Worldwide Technical Research & Development, a position he retained following the merger that created Novartis in 1996. From 1999 until October 2004, Andreas Rummelt served as Head of... View Full Profile

Andreas Rummelt, Ph.D.

In 2006, Andreas von Planta was elected to the Board of Directors of Novartis AG. He has been a member of the Audit and Compliance Committee since 2006. He qualifies as an independent Non-Executive Director. Andreas von Planta is Vice Chairman of Holcim Ltd and the Schweizerische National-Versicherungs-Gesellschaft AG, and is a member of the boards of various Swiss subsidiaries of foreign companies. He is a member of the Board of Editors of the... View Full Profile

Andreas von Planta, Ph.D.

Joerg Reinhardt graduated with a Ph.D. in pharmaceutical sciences from the University of Saarbruecken, Germany in 1981. In April 2006, he became CEO of the new Novartis Vaccines and Diagnostics Division that combines the vaccines and blood-testing businesses of the former Chiron Corp. Prior to this role, Joerg Reinhardt was Head of Development at the Novartis Pharmaceuticals Division, overseeing the company's clinical, pharmaceutical, chemical... View Full Profile

Joerg Reinhardt, Ph.D

Thomas Wellauer graduated with a Ph.D. in systems engineering and an M.S. in chemical engineering from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. He also holds an M.B.A. from the University of Zurich. Thomas Wellauer joined Novartis in 2006 as Head of Corporate Affairs. He started his career with McKinsey and Company, becoming a Partner in 1991 and Senior Partner in 1996. In 1997, he was named CEO of the Winterthur... View Full Profile

Thomas Wellauer, Ph.D

Ulrich Lehner was elected in 2002 to the Board of Directors of Novartis AG. He is Vice Chairman and Lead Director as well as Chairman of the Audit and Compliance Committee. He is also a member of the Chairman's Committee, the Compensation Committee, and the Corporate Governance and Nomination Committee. The Board has appointed him as Audit Committee Financial Expert. He qualifies as an independent Non-Executive Director. Ulrich Lehner is Chairman... View Full Profile

Ulrich Lehner, Ph.D.

Alexandre F. Jetzer has served as a Director since 1996. He is a Non-Executive Director. Alexandre F. Jetzer is also a member of the Supervisory Board of Compagnie Financi're Michelin, Granges-Paccot (FR), Switzerland, and of the Board of the Lucerne Festival Foundation, Lucerne, Switzerland. He is a member of the International Advisory Panel (IAP) on Biotechnology Strategy of the Prime Minister of Malaysia, a member of the Investment Advisory... View Full Profile

Alexandre F. Jetzer

Since 1996 Dr. Vasella has served as Chief Executive Officer of the Group and as executive member of the Board of Directors. In 1999, he additionally was appointed Chairman of the Board of Directors. Dr. Vasella is a member of the Board of Directors of Pepsico, Inc., United States, a member of the Board of Dean's Advisors at the Harvard Business School, and a member of the INSEAD Board of Directors. Dr. Vasella is also a member of the... View Full Profile

Dr. Daniel Vasella

Since 1996 Dr. Vasella has served as Chief Executive Officer of the Group and as executive member of the Board of Directors. In 1999, he additionally was appointed Chairman of the Board of Directors. Dr. Vasella is a member of the Board of Directors of Pepsico, Inc., United States, a member of the Board of Dean's Advisors at the Harvard Business School, and a member of the INSEAD Board of Directors. Dr. Vasella is also a member of the... View Full Profile

Dr. Paul Choffat

Since 1996 Dr. Vasella has served as Chief Executive Officer of the Group and as executive member of the Board of Directors. In 1999, he additionally was appointed Chairman of the Board of Directors. Dr. Vasella is a member of the Board of Directors of Pepsico, Inc., United States, a member of the Board of Dean's Advisors at the Harvard Business School, and a member of the INSEAD Board of Directors. Dr. Vasella is also a member of the... View Full Profile

Dr. Urs Barlocher

Hans-Joerg Rudloff was elected in 1996 to the Board of Directors of Novartis AG. He serves as Vice Chairman as well as Chairman of the Compensation Committee. He is also a member of the Chairman's Committee and the Audit and Compliance Committee. The Board has appointed him as Audit Committee Financial Expert. He qualifies as an independent Non-Executive Director. Hans-Joerg Rudloff joined Barclays Capital in 1998, where he is presently Chairman.... View Full Profile

Hans-Joerg Rudloff

Dr. Burckhardt has been a member of the Board of Directors since 1996. He qualifies as an independent Non-Executive Director. From 1982 to 2004 Dr. Burckhardt was the Chairman of the Novartis (formerly Sandoz) Foundation for Biomedical Research in Switzerland. Since 1982, Dr. Burckhardt has been the Head of the Department of Internal Medicine at the University Hospital of Lausanne, then chief of medical service A, until 2004. Since 1990, he has... View Full Profile

Dr. Peter Burckhardt

Dr. Zinkernagel was elected to the Board of Directors of Novartis AG. He has been a member of the Corporate Governance and Nomination Committee since 2001. He qualifies as an independent Non-Executive Director. Rolf M. Zinkernagel is a member of the Swiss Society of Allergy and Immunology, the American Associations of Immunologists and of Pathologists, the ENI European Network of Immunological Institutions, member of the Advisory Council, BMS... View Full Profile

Dr. Rolf M. Zinkernagel, M.D.

Thomas Ebeling graduated from the University of Hamburg, Germany, with a degree in psychology. From 1987 to 1991, he held several positions of increasing responsibility at Reemstma Germany. In 1991, he joined Pepsi-Cola Germany as Marketing Director. He became Marketing Director for Germany and Austria in 1993, and was National Sales and Franchise Director for Pepsi's retail and on-premise sales from 1994. He then served as General Manager of... View Full Profile

Thomas Ebeling

Pierre Landolt has served as a Director since 1996. He has been a member of the Corporate Governance and Nomination Committee since 2006. He qualifies as an independent Non-Executive Director. Pierre Landolt is President of the Sandoz Family Foundation, Glarus, Switzerland; Chairman of the Board of Directors of Emasan AG, Basel, Switzerland; of Vaucher Manufacture Fleurier SA, Fleurier, Switzerland; and of the Instituto Estrela de Formento ao... View Full Profile

Pierre Landolt

William W. George was elected in 1999 to the Board of Directors of Novartis AG. He is Chairman of the Corporate Governance and Nomination Committee as well as a member of the Chairman's Committee and the Compensation Committee. He qualifies as an independent Non-Executive Director. William W. George is a member of the Boards of Directors of Goldman Sachs and Exxon Mobil. William W. George is Professor of Management Practice at Harvard Business... View Full Profile

William W. George

Marjorie Yang was elected in 2007 to the Board of Directors of Novartis AG with effect from January 1, 2008. She qualifies as an independent Non-Executive Director. Marjorie M. Yang is Chairman and CEO of the Esquel Group. She currently sits on the boards of Swire Pacific and The Hong Kong and Shangai Banking Corporation Limited. She is also a member of the National Committee of the Chinese People's Political Consultative Conference, Chairman of... View Full Profile

Marjorie M. Yang

Joseph Jimenez graduated with a B.A. degree from Stanford University in 1982 and earned an M.B.A. from the University of California, Berkley in 1984. He began his career at The Clorox Company and later served as president of two operating divisions at ConAgra. In 1998, he joined the H.J. Heinz Company and was named President and Chief Executive Officer of the North America business. He later served from 2002 to 2006 as President and Chief... View Full Profile

Joseph Jimenez

Top Competitors: NVS

View Detailed Competitors Chart

Insider Trends: NVS
Sentiment for NVS is —
- 0M
- 2M
- 4M
- 6M
- Market Value of Insider Sales
- Market Value of Insider Purchases
Total dollar value of all insider purchases and sales over 12 months
View All Insider Sentiment

Insider Transactions: NVS

Date	Name	Shares	Transaction Type	Market Value
03/25/08	FISHMAN MARK C	10,200	Planned Sale	$512,034.00
10/01/07	EPSTEIN DAVID	6,212	Planned Sale	$339,978.00

View All Insider Activity

Ownership Breakdown : NVS

Large Block Holder Type	Number
Institutions	585.00
Mutual Fund	379.00
Other Major	2.00

Full Details

Indices : NVS

Symbol	Name	Last Trade	Change

View all Indices that include NVS

Short Interest Volume: NVS

Data as of —

Current Short Interest Shares	3.38 M
Current Short Interest Ratio	1.90
Float	—

Short Interest as % of Float	—
Average Daily Volume	2.04 M
Outstanding Shares	2.64 B

Full Details

SEC Filings: NVS

Accepted Date	Description
07/18/2008	SEC Filing: Foreign Issuer Report
07/16/2008	SEC Filing: Foreign Issuer Report
07/10/2008	SEC Filing: Foreign Issuer Report

View all SEC Filings

Get Profile Details for:

- Help & Feedback

Market Movers

Related Resources

My Portfolios

AOL Real-Time Streaming Quotes

NOVARTIS A G

NVS

Stock price

58.79 -1.06 -1.77%

as of 03:06 PM EDT on 07/25/2008 in USD (NYSE Delay: 20 mins.)
Analyst Consensus
- Strong Buy
- Buy
- Hold
- Sell
- Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: NVS

Quote Search Search the Web Search

Live Updates:

Ticker

Dynamic view of the market

NOVARTIS A G

NVS

Stock price

Extended Hours

Analyst Consensus

NOVARTIS A G Profile

Key Executives: NVS

Top Competitors: NVS

Insider Trends: NVS

Insider Transactions: NVS

Ownership Breakdown : NVS

Indices : NVS

Short Interest Volume: NVS

SEC Filings: NVS

Quote Details

Classic Chart

Advanced Chart BETA

Real-Time Headlines

Message Boards

Profile

Earnings Analysis

Event Calendar

Financials

Market Movers

Related Resources

NOVARTIS A G

NVS

Stock price

Analyst Consensus

More in Money & Finance